Metabolic profiling reveals differences in concentrations of oxylipins and fatty acids secreted by the infrapatellar fat pad of donors with end-stage osteoarthritis and normal donors

Arthritis and Rheumatism

Volumn 65, Issue 10, 2013, Pages 2606-2614

  Gierman, L M ^a   Wopereis, S ^b   Van El, B ^b   Verheij, E R ^b   Werff Van Der Vat, B J C ^b   Bastiaansen Jenniskens, Y M ^c   Van Osch, G J V M ^c   Kloppenburg, M ^a   Stojanovic Susulic, V ^d   Huizinga, T W J ^a   Zuurmond, A M ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; FATTY ACID; LIPOXIN A; OXYLIPIN; THROMBOXANE B2;

ACID SECRETION; ADULT; ARTICLE; CLINICAL ARTICLE; DONOR; EPIDIDYMIS FAT; HUMAN; HUMAN TISSUE; INFRAPATELLAR FAT PAD; JOINT PROSTHESIS; JOINT SURGERY; LIQUID CHROMATOGRAPHY; OSTEOARTHRITIS; OUTCOME ASSESSMENT; PARTIAL LEAST SQUARES REGRESSION; PATELLA TENDON; PREDICTIVE VALUE; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

ADIPOSE TISSUE; AGED; BIOLOGICAL MARKERS; CELLS, CULTURED; CHROMATOGRAPHY, LIQUID; FATTY ACIDS; FEMALE; HUMANS; MALE; METABOLOME; MIDDLE AGED; MODELS, STATISTICAL; OSTEOARTHRITIS; OXYLIPINS; PATELLA; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; TANDEM MASS SPECTROMETRY; TISSUE DONORS;

EID: 84885161471     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.38081     Document Type: Article

References (38)

1. Hunter DJ, Felson DT,. Osteoarthritis. BMJ 2006; 332: 639-42.
2. Felson DT,. Developments in the clinical understanding of osteoarthritis. Arthritis Res Ther 2009; 11: 203.
3. Loeser RF, Goldring SR, Scanzello CR, Goldring MB,. Osteoarthritis: a disease of the joint as an organ [review]. Arthritis Rheum 2012; 64: 1697-707.
4. Yusuf E, Nelissen RG, Ioan-Facsinay A, Stojanovic-Susulic V, DeGroot J, van Osch G, et al. Association between weight or body mass index and hand osteoarthritis: a systematic review. Ann Rheum Dis 2010; 69: 761-5.
5. Toda Y, Toda T, Takemura S, Wada T, Morimoto T, Ogawa R,. Change in body fat, but not body weight or metabolic correlates of obesity, is related to symptomatic relief of obese patients with knee osteoarthritis after a weight control program. J Rheumatol 1998; 25: 2181-6.
6. Kershaw EE, Flier JS,. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89: 2548-56.
7. Gallagher J, Tierney P, Murray P, O'Brien M,. The infrapatellar fat pad: anatomy and clinical correlations. Knee Surg Sports Traumatol Arthrosc 2005; 13: 268-72.
8. Clockaerts S, Bastiaansen-Jenniskens YM, Runhaar J, Van Osch GJ, Van Offel JF, Verhaar JA, et al. The infrapatellar fat pad should be considered as an active osteoarthritic joint tissue: a narrative review. Osteoarthritis Cartilage 2010; 18: 876-82.
9. Ushiyama T, Chano T, Inoue K, Matsusue Y,. Cytokine production in the infrapatellar fat pad: another source of cytokines in knee synovial fluids. Ann Rheum Dis 2003; 62: 108-12.
10. Klein-Wieringa IR, Kloppenburg M, Bastiaansen-Jenniskens YM, Yusuf E, Kwekkeboom JC, El-Bannoudi H, et al. The infrapatellar fat pad of patients with osteoarthritis has an inflammatory phenotype. Ann Rheum Dis 2011; 70: 851-7.
11. Bastiaansen-Jenniskens YM, Clockaerts S, Feijt C, Zuurmond AM, Stojanovic-Susulic V, Bridts C, et al. Infrapatellar fat pad of patients with end-stage osteoarthritis inhibits catabolic mediators in cartilage. Ann Rheum Dis 2012; 71: 288-94.
12. Lewis RA,. Interactions of eicosanoids and cytokines in immune regulation. Adv Prostaglandin Thromboxane Leukot Res 1990; 20: 170-8.
13. Tilley SL, Coffman TM, Koller BH,. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J Clin Invest 2001; 108: 15-23.
14. Haeggstrom JZ, Funk CD,. Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease. Chem Rev 2011; 111: 5866-98.
15. Flower RJ, Perretti M,. Controlling inflammation: a fat chance? J Exp Med 2005; 201: 671-4.
16. Sato T, Konomi K, Fujii R, Aono H, Aratani S, Yagishita N, et al. Prostaglandin EP2 receptor signalling inhibits the expression of matrix metalloproteinase 13 in human osteoarthritic chondrocytes. Ann Rheum Dis 2011; 70: 221-6.
17. 2 at very low concentrations suppresses collagen cleavage in cultured human osteoarthritic articular cartilage: this involves a decrease in expression of proinflammatory genes, collagenases and COL10A1, a gene linked to chondrocyte hypertrophy. Arthritis Res Ther 2007; 9: R75.
18. Bertin P, Lapicque F, Payan E, Rigaud M, Bailleul F, Jaeger S, et al. Sodium naproxen: concentration and effect on inflammatory response mediators in human rheumatoid synovial fluid. Eur J Clin Pharmacol 1994; 46: 3-7.
19. Molloy ES, McCarthy GM,. Eicosanoids, osteoarthritis, and crystal deposition diseases. Curr Opin Rheumatol 2005; 17: 346-50.
20. Laufer S,. Role of eicosanoids in structural degradation in osteoarthritis. Curr Opin Rheumatol 2003; 15: 623-7.
21. Balvers MG, Verhoeckx KC, Meijerink J, Bijlsma S, Rubingh CM, Wortelboer HM, et al. Time-dependent effect of in vivo inflammation on eicosanoid and endocannabinoid levels in plasma, liver, ileum and adipose tissue in C57BL/6 mice fed a fish-oil diet. Int Immunopharmacol 2012; 13: 204-14.
22. Barham JB, Edens MB, Fonteh AN, Johnson MM, Easter L, Chilton FH,. Addition of eicosapentaenoic acid to γ-linolenic acid- supplemented diets prevents serum arachidonic acid accumulation in humans. J Nutr 2000; 130: 1925-31.
23. Balvers MG, Verhoeckx KC, Bijlsma S, Rubingh CM, Meijerink J, Wortelboer HM, et al. Fish oil and inflammatory status alter the n-3 to n-6 balance of the endocannabinoid and oxylipin metabolomes in mouse plasma and tissues. Metabolomics 2012; 8: 1130-47.
24. Barker M, Rayens W,. Partial least squares for discrimination. J Chemometrics 2003; 17: 166-73.
25. Smit S, van Breemen MJ, Hoefsloot HC, Smilde AK, Aerts JM, de Koster CG,. Assessing the statistical validity of proteomics based biomarkers. Anal Chim Acta 2007; 592: 210-7.
26. Attur M, Dave M, Abramson SB, Amin A,. Activation of diverse eicosanoid pathways in osteoarthritic cartilage: a lipidomic and genomic analysis. Bull NYU Hosp Jt Dis 2012; 70: 99-108.
27. Hashimoto A, Hayashi I, Murakami Y, Sato Y, Kitasato H, Matsushita R, et al. Antiinflammatory mediator lipoxin A4 and its receptor in synovitis of patients with rheumatoid arthritis. J Rheumatol 2007; 34: 2144-53.
28. Sodin-Semrl S, Spagnolo A, Barbaro B, Varga J, Fiore S,. Lipoxin A4 counteracts synergistic activation of human fibroblast-like synoviocytes. Int J Immunopathol Pharmacol 2004; 17: 15-25.
29. Sodin-Semrl S, Taddeo B, Tseng D, Varga J, Fiore S,. Lipoxin A4 inhibits IL-1 β-induced IL-6, IL-8, and matrix metalloproteinase-3 production in human synovial fibroblasts and enhances synthesis of tissue inhibitors of metalloproteinases. J Immunol 2000; 164: 2660-6.
30. Kronke G, Katzenbeisser J, Uderhardt S, Zaiss MM, Scholtysek C, Schabbauer G, et al. 12/15-lipoxygenase counteracts inflammation and tissue damage in arthritis. J Immunol 2009; 183: 3383-9.
31. Fiore S, Antico G, Aloman M, Sodin-Semrl S,. Lipoxin A4 biology in the human synovium: role of the ALX signaling pathways in modulation of inflammatory arthritis. Prostaglandins Leukot Essent Fatty Acids 2005; 73: 189-96.
32. 2 production in biological fluids. Anal Biochem 2008; 372: 41-51.
33. Maskrey BH, O'Donnell VB,. Analysis of eicosanoids and related lipid mediators using mass spectrometry. Biochem Soc Trans 2008; 36: 1055-9.
34. Lopez HL,. Nutritional interventions to prevent and treat osteoarthritis. Part I. Focus on fatty acids and macronutrients. PM R 2012; 4: S145-54.
35. Knott L, Avery NC, Hollander AP, Tarlton JF,. Regulation of osteoarthritis by omega-3 (n-3) polyunsaturated fatty acids in a naturally occurring model of disease. Osteoarthritis Cartilage 2011; 19: 1150-7.
36. Pelletier JP, Martel-Pelletier J, Abramson SB,. Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets [review]. Arthritis Rheum 2001; 44: 1237-47.
37. Lee CH,. Resolvins as new fascinating drug candidates for inflammatory diseases. Arch Pharm Res 2012; 35: 3-7.
38. De Grauw JC, van de Lest CH, van Weeren PR,. A targeted lipidomics approach to the study of eicosanoid release in synovial joints. Arthritis Res Ther 2011; 13: R123.